-
Dr Sanil RegeJuly 25, 2022
Time to read: 17–20 minutes
When patients with Major Depressive Disorder (MDD) don’t respond to medication, clinicians have three options: Increase dose, switch or augment....
READ MOREJuly 20, 2022In this video, Dr Sanil Rege, Consultant Psychiatrist and Academic Lead of Psych Scene talks to Prof Ian Hickie and A/Prof Liz...
READ MOREJune 30, 2022In this video Dr Sanil Rege, Consultant Psychiatrist covers the mechanism of action of Agomelatine. Agomelatine has recently been TGA approved fo...
READ MOREJune 20, 2022Long-acting injectable antipsychotics (LAIs) are an effective treatment option in schizophrenia. However, they are often viewed negatively by clinicia...
READ MOREDr Sanil RegeJune 17, 2022Time to read: 10 minutes
Brexpiprazole [7-{4-[4-(1-benzothiophene-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one] is a novel atypical antipsychotic that is structurally similar ...
READ MOREDr Sanil RegeJune 9, 2022Time to read: 8 minutes
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by inattention, disorganisation, and/or hyperactive impul...
READ MOREDr Sanil RegeJune 3, 2022Time to read: 4 minutes
Clozapine is metabolised in the liver predominantly by CYP1A2 and partially (35% ) by CYP3A4. It is, however, important to recognise that in some patien...
READ MOREDr Sanil RegeMay 30, 2022Time to read: 7 minutes
Lemborexant (DAYVIGO) is a dual orexin receptor antagonist (DORA) that was approved in 2019 for the treatment of sleep-onset and/or sleep maintenance in...
READ MOREDr Sanil RegeApril 26, 2022Time to read: 11–13 minutes
Lithium-induced nephropathy has been reported since the 1970s and covers many kidney function impairments. ...
READ MORE